The Role of DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Nursing Symposium Video Proceedings

Faculty

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.

LEARNING OBJECTIVES

• Appraise the scientific rationale for and mechanism of action of the DLL3-targeting bispecific T-cell engagers (BiTEs) used as therapy for patients with small cell lung cancer (SCLC).
• Evaluate available research findings with DLL3-targeting BiTEs for relapsed/refractory SCLC, and counsel patients with this disease regarding the risks and benefits of this novel approach.
• Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with DLL3-targeting BiTEs employed in the care of patients with SCLC, and develop strategies to optimally identify and manage the symptoms of these side effects.
• Recognize the spectrum, frequency and severity of other adverse events associated with DLL3-targeting BiTEs, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Appreciate the practical administration requirements associated with DLL3-targeting BiTEs in order to appropriately educate eligible patients.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/BiTEsSCLC/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/BiTEsSCLC/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Anne Chiang, MD, PhD
Associate Professor
Yale University School of Medicine
Deputy Chief Medical Officer
Chief Integration Officer
Smilow Cancer Hospital
New Haven, Connecticut

Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Fosun Pharma, Genentech, a member of the Roche Group, Janssen Biotech Inc, Zai Lab; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Zai Lab; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Internal Education Lecture on SCLC: Jazz Pharmaceuticals Inc.

Elizabeth Krueger, NP
Nurse Practitioner
Massachusetts General Hospital Center for Thoracic Cancers
Boston, Massachusetts

No relevant financial relationships to disclose.

Beth Sandy, MSN, CRNP, FAPO
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committees: Pfizer Inc; Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc.

Erin Schenk, MD, PhD
Assistant Professor
Thoracic Oncology
Division of Medical Oncology, Department of Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Advisory Committees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, CDR-Life, Harpoon Therapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Takeda Pharmaceuticals USA Inc, Thetis Pharmaceuticals LLC; Consulting Agreements: Aadi Bioscience, ALIGN2ACTION Inc, Axon Advisors, BeiGeneius, Expert Connect, GlobalData, Guidepoint Global LLC, HCG, Slingshot Insights, The Scieomics Group, Third Bridge, WC Communications; Data and Safety Monitoring Boards/Committees: Amgen Inc; Speakers Bureaus: Curio Science, Harpoon Therapeutics, Janssen Biotech Inc, Nuvation Bio; Stock Options — Private Companies: Thetis Pharmaceuticals LLC; Nonrelevant Financial Relationships: ASCO Direct, Cancer Therapy Advisor, Horizon CME, IDEOlogy Health, Medscape, OncLive, ROS1ders.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Amgen Inc.

Release date: May 2025
Expiration date: May 2026

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Chiang

Module 1: Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management

Kim SY et al. Small cell lung cancer: A review. JAMA 2025;[Online ahead of print]. Abstract

Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39(6):619-30. Abstract

Paz-Ares LG et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. ESMO 2021;Abstract LBA61.

Spigel DR et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024;Abstract LBA5.

Module 2: Current Role of Tarlatamab in Therapy for SCLC

Ahn M-J et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. Abstract

Chiang AC et al. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open 2025;10(4):104538. Abstract

Chiang AC et al. Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. ESMO Immuno-Oncology 2024;Abstract 155P.

Owen DH et al. DLL3: An emerging target in small cell lung cancer. J Hematol Oncol 2019;12(1):61. Abstract

Subbiah V et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020;150:90-6. Abstract

Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract

 

Dr Schenk

Module 3: Future Directions in the Management of SCLC

Beltran H et al. Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). ASCO 2024;Abstract 8090.

Bragasin EI et al. Advances in adoptive cell therapies in small cell lung cancer. Explor Target Antitumor Ther 2025;6:1002302. Abstract

Chen Y et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391(14):1313-27. Abstract

Hummel H et al. Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). European Lung Cancer Congress 2024;Abstract 214TiP.

Meng Y et al. Antibody-drug conjugates treatment of small cell lung cancer: Advances in clinical research. Discov Oncol 2024;15(1):327. Abstract

Paz-Ares LG et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). ASCO 2023;Abstract TPS8611.

Rudin CM et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of Ideate-lung01. WCLC 2024;Abstract OA04.03.

Rudin CM et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol 2023;16(1):66. Abstract

Wermke M et al. Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data. ESMO 2024;Abstract 670P.

Module 4: Unique Considerations in SCLC Management

Chow R et al. Management of malignant superior vena cava syndrome. Ann Palliat Med 2024;13(3):620-6. Abstract

Lukas RV et al. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget 2017;8(41):71223. Abstract

Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664-72. Abstract

Soomro Z et al. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis 2020;12(10):6253-63. Abstract

Zeng H et al. Risk factors for brain metastases in patients with small cell lung cancer: A systematic review and meta-analysis. Front Oncol 2022;12:889161. Abstract

 

Ms Sandy

Module 4

Ahn M-J et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. Abstract